Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883086 | 0.79 | KMT2A (0.53) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL31009554 | 0.78 | KMT2A (0.44) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL3222113 | 0.76 | RAB9A (0.43) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL10271343 | 0.75 | KMT2A (0.49) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL19153125 | 0.73 | S100A4 (0.39) | RAB9AL3MBTL1KDM4EMAPT | |
| SCHEMBL6256784 | 0.71 | MEN1 (0.38) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| SCHEMBL27708952 | 0.69 | CLK4 (0.49) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL31460555 | 0.66 | RAB9A (0.48) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL10473024 | 0.66 | RAB9A (0.43) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL17875905 | 0.65 | CYP19A1 (0.40) | KMT2AMEN1RAB9AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | KMT2A 4150/4885MEN1 4474/4885RAB9A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.